Last reviewed · How we verify
Influenza Trivalent Inactivated vaccines
Influenza Trivalent Inactivated vaccines is a Biologic drug developed by Novartis. It is currently in Phase 2 development.
At a glance
| Generic name | Influenza Trivalent Inactivated vaccines |
|---|---|
| Sponsor | Novartis |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Longitudinal Tracking of Bone Marrow Plasma Cell Responses to Licensed Human Vaccines (PHASE4)
- Influenza Vaccination Strategy for Patients With Hematologic Malignancy (PHASE3)
- Immunogenicity and Safety Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) in Adults Aged 50 Years and Older (PHASE3)
- Study to Evaluate Immunogenicity and Safety of a High-Dose Influenza Vaccine in Adults 50 Through 64 Years of Age (PHASE3)
- Immunogenicity Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) to Prevent Culture Confirmed Influenza Infection (PHASE3)
- High vs. Standard Dose Influenza Vaccines in Lung Transplant (Repeater) (PHASE2)
- A Phase 0 Window of Opportunity Trial of Intratumoral Seasonal Influenza Immunization in Cutaneous Squamous Cell Carcinoma (CSCC) Patients Awaiting Curative Excision (EARLY_PHASE1)
- Immunogenicity and Safety of Butantan Quadrivalent Influenza Vaccine (Split Virion, Inactivated) in Infants and Children . (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Influenza Trivalent Inactivated vaccines CI brief — competitive landscape report
- Influenza Trivalent Inactivated vaccines updates RSS · CI watch RSS
- Novartis portfolio CI
Frequently asked questions about Influenza Trivalent Inactivated vaccines
What is Influenza Trivalent Inactivated vaccines?
Influenza Trivalent Inactivated vaccines is a Biologic drug developed by Novartis.
Who makes Influenza Trivalent Inactivated vaccines?
Influenza Trivalent Inactivated vaccines is developed by Novartis (see full Novartis pipeline at /company/novartis).
What development phase is Influenza Trivalent Inactivated vaccines in?
Influenza Trivalent Inactivated vaccines is in Phase 2.